McClurg Dylan P, Urquhart Gordan, McGoldrick Trevor, Chatterji Subarnarekha, Miedzybrodzka Zosia, Speirs Valerie, Elsberger Beatrix
School of Medicine, Medical Sciences and Nutrition, University of Aberdeen, Foresterhill, Aberdeen AB25 2ZD, UK.
Aberdeen Royal Infirmary, Department of Oncology, Foresterhill Road, Aberdeen AB25 2ZN, UK.
Cancers (Basel). 2022 Jun 28;14(13):3175. doi: 10.3390/cancers14133175.
Male breast cancer (MBC) is a rare disease that accounts for less than 1% of all breast cancers and male malignancies. Despite recognised clinico-pathological and molecular differences to female breast cancer (FBC), the clinical management of MBC follows established FBC treatment strategies. Loss of function mutations in the DNA damage response genes and , have been strongly implicated in the pathogenesis of MBC. While there have been extensive clinical advancements in other -related malignancies, including FBC, improvements in MBC remain stagnant. Here we present a review that highlights the lack of treatment evidence for -related MBC and the required national and global collaborative effort to address this unmet need. In doing so, we summarise the transformative clinical advancements with poly(ADP-ribose) polymerase (PARP) inhibitors in other -related cancers namely, FBC and prostate cancer.
男性乳腺癌（MBC）是一种罕见疾病，在所有乳腺癌和男性恶性肿瘤中占比不到1%。尽管已认识到MBC与女性乳腺癌（FBC）在临床病理和分子方面存在差异，但MBC的临床管理仍遵循既定的FBC治疗策略。DNA损伤反应基因 和 的功能缺失突变与MBC的发病机制密切相关。虽然在包括FBC在内的其他 相关恶性肿瘤方面已经取得了广泛的临床进展，但MBC的改善仍然停滞不前。在此，我们发表一篇综述，强调缺乏与 相关的MBC的治疗证据，以及国家和全球为满足这一未满足需求而需要开展的合作努力。在此过程中，我们总结了聚（ADP-核糖）聚合酶（PARP）抑制剂在其他 相关癌症（即FBC和前列腺癌）中带来的变革性临床进展。
